Join
Live feed
·
PRReleasevia Quantisnow
Biogen Inc. logo

FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review

ByQuantisnow·Wall Street's wire, on your screen.
BIIB· Biogen Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BIIB (Biogen Inc.) and more on Quantisnow.